Paclitaxel-Potentiated Photodynamic Theranostics for Synergistic Tumor Ablation and Precise Anticancer Efficacy Monitoring

• DOI: 10.1021/acsami.9b19073
• Publication Date: 2020-01-08T08:57:37Z
• Authors: Xiuxia Wang; Junwei Tong; Zhenyan He; Xiangliang Yang; Fanling Meng; Huageng Liang; Xiaoping Zhang; Liang Luo
• Keywords: Tumor ablation

Photodynamic theranostics that allows for concurrent photodynamic therapy (PDT) and precise therapeutic response report has emerged as an intriguing direction in the development of precision medicine. An ultra-efficient platform was developed here based on combining potentiating a theranostic photosensitizer, TPCI, with other therapies synergistic anticancer effect synchronous self-reporting response. In this study, TPCI chemotherapy agent paclitaxel (PTX) were co-encapsulated liposomes, which exhibited superb against series tumor cell lines. The potency both drugs had been boosted up to 30-fold compared sole PDT or chemotherapy. More strikingly, released lighted nuclei dead cells, triggered either by chemotherapy, through binding chromatin activating its aggregation-induced emission, therefore combined real time. vivo study using mouse model bearing PC3 prostate cells demonstrated effective ablation tumors initial sizes 200 mm3 early monitoring TPCI/PTX@Lipo. This PTX-potentiated strategy herein represented new prototype nanomedicine therapy.